hydroxyitraconazole has been researched along with Hematologic Malignancies in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheong, JW; Joo, YD; Kang, HJ; Kim, H; Kim, HG; Kim, HY; Kim, JS; Kim, JY; Kim, SH; Kim, YK; Kim, YS; Lee, DG; Lee, JH; Min, YH; Mun, YC; Park, J; Ryoo, HM; Yi, HG | 1 |
| Bergmann, L; Böhme, A; Hoelzer, D; Just-Nübling, G; Shah, PM; Stille, W | 1 |
| Archimbaud, E; Coronel, B; Dorez, D; Levron, JC; Mercatello, A; Van Devenne, A | 1 |
1 trial(s) available for hydroxyitraconazole and Hematologic Malignancies
| Article | Year |
|---|---|
Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antifungal Agents; Female; Hematologic Neoplasms; Humans; Itraconazole; Male; Middle Aged; Mycoses; Prospective Studies | 1996 |
2 other study(ies) available for hydroxyitraconazole and Hematologic Malignancies
| Article | Year |
|---|---|
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifungal Agents; Chemotherapy-Induced Febrile Neutropenia; Drug Monitoring; Female; Hematologic Neoplasms; Humans; Itraconazole; Male; Middle Aged; Mycoses; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Itraconazole lung concentrations in haematological patients.
Topics: Adult; Aged; Antifungal Agents; Chromatography, High Pressure Liquid; Female; Hematologic Neoplasms; Humans; Itraconazole; Lung; Male; Middle Aged | 2000 |